The document discusses personalized medicine in Switzerland, highlighting the modest political and media response despite its ambitious concept. It notes the importance of standardized electronic medical files and addresses the complexities surrounding genetic testing, data privacy, and healthcare economics. The Swiss Academy of Medical Sciences emphasizes the need for action, information dissemination, and innovative approaches as the country prepares for advancements in personalized medicine.

1. www.risicare.ch
Personalized Medicine
in Switzerland

2. 2Swiss Academy of Medical Sciences / TA-SWISS
• ambitious concept
• modest response in politics and media so far
• sceptical voices prevail
• «Marketing instrument of the pharmaceutical
industry»
• «We will be the gravediggers of our own
private sphere»
• debate concentrates on special aspects
like genetic testing
Public perception

3. 3Swiss Academy of Medical Sciences / TA-SWISS
• strong privately financed research
• no explicit national programme
• multitude of individual projects
• need for complementing research
• legal aspects
• bioinformatics
• communication
• etc.
Research

4. 4Swiss Academy of Medical Sciences / TA-SWISS
• well established in centres of excellence
for example in university hospitals
• but: even specialists often overtaxed
• personalized medicine:
medicine for the person?
• the boundaries between
«healthy» and «ill» vanish
Medical practice

5. 5Swiss Academy of Medical Sciences / TA-SWISS
• strategy of the
federal administration
• central importance of standardised
electronic medical file
• federalist structure of health system
• niche for private services
• strong need for standardisation
E-Health

6. 6Swiss Academy of Medical Sciences / TA-SWISS
• collection of data
• types of data
• integration in electronic medical file
• open source vs. data protection
• new forms of research (crowd sourcing)
• data processing, data mining
• creating new assets
• area of conflict between
«private» und «public»
Internet and Social Media

7. 7Swiss Academy of Medical Sciences / TA-SWISS
• ban for direct to consumer genetic testing
• different regulations for the dealing with
genetic biomarkers and other biomarkers
• licensing of drugs tailor-made for blockbusters
• from informed consent to
«informed lack of knowledge»?
Legal challenges

8. 8Swiss Academy of Medical Sciences / TA-SWISS
• We are not yet well prepared
for a real breakthrough of personalized medicine
Present situation

9. 9Swiss Academy of Medical Sciences / TA-SWISS
• high potentials
• progress, especially in oncology
• limits of effectiveness
• importance for pharmaceutical industry
• need for action
• information and education
for physicians and patients
• label for physicians with special
competence
• improvements in medical genetics
and the use of case history
• evaluation of direct to customer
services
Position of the Swiss Academy of Medical Sciences

10. 10Swiss Academy of Medical Sciences / TA-SWISS
• strong pharmaceutical and medtech industry
in Switzerland
• need for innovative concepts
• alternative to the blockbuster-model
- with chances and risks
• interest in limiting costs for clinical studies
• new services for new customers
• consequences for political economy
open
Economic aspects

11. 11Swiss Academy of Medical Sciences / TA-SWISS
• obligatory health insurance:
principle of solidarity between the healthy and the ill, younger
and older people, men and women well established
• solidarity in society:
important role of personal responsibility / personal autonomy
decreasing patience with those, who do not care for their
health?
• balance between individual capacities
and individual needs
Concept of solidarity

12. 12Swiss Academy of Medical Sciences / TA-SWISS
• technology assessment
as a catalyst
• intensifying the political
and societal debate
Outlook

13. 13Swiss Academy of Medical Sciences / TA-SWISS
Thank you
for your attention